Aktuelle Behandlungskonzepte bei Heparin-induzierterThrombozytopenie

Deutsche Medizinische Wochenschrift

Volumn 124, Issue 28-29, 1999, Pages 865-873

  Ranze, O ^a   Greinacher, A ^a   Hohlfeld, Redaktion R ^a   Kabelitz, München D ^a   Kremer, Langen B ^a   Lode, Kiel H ^a   Meinertz, Berlin T ^a   Philipp, Hamburg Th ^a   Sauerbruch, Essen T ^a   Werdan, Bonn K ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANCROD; ANTICOAGULANT AGENT; ANTIVITAMIN K; ARGATROBAN; BLOOD CLOTTING FACTOR 10; DANAPAROID; DESULFATOHIRUDIN; DEXTRAN; FIBRINOGEN RECEPTOR; HEPARIN; HEPARIN COFACTOR II; HIRUDIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LEPIRUDIN; PROTHROMBIN; THROMBOCYTE FACTOR 4;

ARTICLE; BLOOD CLOT LYSIS; CLINICAL FEATURE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; HEMODIALYSIS; HEMOFILTRATION; HEPARINIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PLASMAPHERESIS; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOEMBOLISM;

ADULT; ANTICOAGULANTS; CHILD; CHONDROITIN SULFATES; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DERMATAN SULFATE; DRUG COMBINATIONS; FEMALE; HEPARIN; HEPARITIN SULFATE; HIRUDINS; HUMANS; MALE; PREGNANCY; THROMBOCYTOPENIA;

EID: 0033575297     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1024433     Document Type: Article

References (67)

1. Adkins, J.C, M.I. Wilde Lepirudin. A review of its potential place in management of thrombotic disorders. BioDrugs. 10 (1998), 227-255.
2. Aiach. M., D. Borgel, P. Gaussem. J. Emmerlich, M. Alhenc-Gelas, S. Gandrille Protein C and protein S deficiencies. Sem. Hematol. 34 (1997). 205-217.
3. Amiral. J.; M. Wolf; A. Fischer, C. Boyer-Neumann, A. Vissac, D. Meyer Pathogenicity of IgA and/or IgM antibodies to heparinPF4 complexes in patients with heparin-induced thrombocytopenia. Brit.J. Haematol. 92 (1996). 954-959.
4. Arepally, G., D.B. Cines Heparin-induced thrombocytopenia and thrombosis. Clin. Rev. Allergy Immunol. 16 (1998), 237-247.
5. Bouvier. J.L. P. Lefèvre, P. Villain. A. Elias. G. Habib. T. Gillet. A. Serradimigui Treatment of serious heparin-induced thrombocytopenia by plasma exchange report on 4 cases. Thromb. Res. 51 (1988). 335-336.
6. Bradbrook, I.D., H.N. Magnani, H.C. Moelker, PJ. Morrison, J. Robinson, HJ. Rogers, R.G. Spector, T. van Dinther, H. Wijnand ORG 10172 a low molecular weight heparinoid anticoagulant with a long half-life in man. Brit.J. Clin. Pharmacol. 23 (1987). 667-675.
7. Chong. B.H., C.S. Grace, M.C. Rozenberg Heparin-induced thrombocytopenia effect of heparin platelet antibody on platelets. Brit. J. Haematol. 49 (1981), 531-540.
8. Chong. B.H., F. Ismail. J.F. Cade. A.S. Callus. S. Gordon, C.N. Chesterman Heparin-induced thrombocytopenia. Blood 73 (1989), 1592-1596.
9. Chong, B.H. Heparin-induced thrombocytopenia. Brit. J. Haematol. 89 (1995), 431-439.
10. Compassionate-use of Org 10172 in patients with heparin-induced thrombocytopenia (HIT) or other forms of heparin intolerance (patients treated up to July 31, 1995). N.V. Organon/Oss. 1996 (unveröffentlichter Bericht).
11. Danhof, M., A. de Boer, H.N. Magnani, J.C. Stiekema Pharmocokinetic considerations on Orgaran (Org 10172) therapy. Haemostasis 22 (1992). 73-84.
12. Demers. C. J.S. Ginsberg. P. Brill-Edwards, A. Panju, T.E. Warkentin, D.R. Anderson. C. Turner, J.G. Kelton Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia. Blood 78 (1991), 2194-7.
13. Dickneite, G., U. Nicolay, HJ. Friesen, M. Reers Development of an anti-bleeding agent for recombinant hirudin induced skin bleeding in the pig. Thromb. Haemost. 80 (1998). 192-198.
14. Eichler, P., A. Greinacher Anti-hirudin antibodies induced by recombinant hirudin in the treatment of heparin-induced thrombocytopenia (HIT). Ann. Hematol. 72 (1996) Suppl. A4. (abstract)
15. Emig, U., T. Meyer, A.B. Buchwald Erfolgreiche Lysetherapie einer Vena-cava-inferior- und iliofemoral-Venenthrombose bei Heparin-induzierter Thrombozytopenie Typ II. Dtsch. med. Wschr. 122 (1997). 965-968.
16. Eriksson, B.I.. P.W. Jorgensen, P. Kälebo, P. Mouret, N. Rosencher, P. Bosch, et al. A comparison of recombinant hirudin with a low-molecular weight heparin to prevent thromboembolic complications after total hip replacement. New Eng. J. Med. 337 (1997), 1329-1335.
17. Greinacher, A., U. Liebenhoff. V. Kiefel, P. Presek, C. MuellerEckhardt Heparin-associated thrombocytopenia the effects of various intravenous IgG preparations on antibody mediated platelet activation - a possible new indication for high dose i.v. IgG. Thromb. Haemost. 71 (1994), 641-645.
18. Greinacher. A. Antigen generation in heparin-associated thrombocytopenia. Semin. Thromb. Hemostas. 21 (1995), 106-116.
19. Greinacher, A., S. Alban Heparinoide als eine Alternative für die parenterale Antikoagulation bei Patienten mit Heparin-induzierter Thrombozytopenie. Hämostaseologie 16 (1996), 41-49.
20. Greinacher, A. Heparin-induzierte Thrombozytopenie - Pathogenese und Behandlung. Hämostaseologie 19 (1999), 1-12.
21. Greinacher, A. Rekombinantes Hirudin zur weiteren Antikoagulation bei Patienten mit Heparin-induzierter Thrombozytopenie. Hämostaseologie 19 (1999). 31-44.
22. Greinacher, A.. H. Völpel, U. Janssens, V. Hach-Wunderle, B. Kemkes-Matthes. P. Eichler, H.G. Müller-Veiten. B. Pötzsch Recombinant hirudin (lepirudin) provides safe and effective anti-coagulation in patients with the immunologie type of heparin-induced thrombocytopenia. Circulation 99 (1999), 73-80.
23. Hach-Wunderle, V.. K. Kainer, G. Salzmann, G. Müller-Berghaus. B. Pötzsch Heparin-related thrombosis despite normal platelet counts in vascular surgery. Amer. J. Surg. 173 (1997), 117-119.
24. Hempel, S., N. Lubenow, A. Greinacher Haemodialysis or haemofiltration with r-hirudin in patients with heparin-induced thrombocytopenia type II.
25. Henny. C.P., H. Ten Gate. J.W. Ten Gate. S. Surachno, H. van Bronswijk, J.M. Wilmink. PA Ockelford Use of a new heparinoid as anticoagulant during acute haemodialysis of patients with bleeding complications. Lancet. 23 (1983), 890-893.
26. Hermann, J.-P.R.. M.J.B. Kutryk, P.W. Serruys Clinical trials of direct thrombin inhibitors during invasive procedures. Thromb. Haemost. 78 (1997). 367-376.
27. Huhle, G., U. Hoffmann. X.H. Song, D.L Heene. J. Harenberg Immunantwort auf rekombinantes Hirudin. Eine Übersicht. Hämostaseologie 19 (1999), 50-54.
28. Ireland. H., D.A. Lane; A. Flynn, E. Anastassiades. J.R. Curtis The anticoagulant effect of heparinoid Org 10172 during haemodialysis an objective assessment. Thromb. Haemost. 55 (1986). 271-275.
29. Koster, A., H. Kuppe, R. Hetzer, R. Sodian, G.J. Crystal, F. Mertzlufft Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type 11 employing recombinant hirudin. Anesthesiology 89(1998), 777-780.
30. Lewis, B.E., E.D. Grassman, L Wrona. Y. Rangel Novastan anti-coagulation during renal stent implant in a patient with heparin-induced thrombocytopenia. Blood. Coagul. Fibrinolysis 8 (1997). 54-58.
31. Lewis. B.E. mündliche Präsentation während des ISTH-Kongresses 1997, Florenz.
32. Lewis, B.E., Y. Rangel. J. Fareed The first report of successful carotid stent implant using argatroban anticoagulation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome a case report. Angiology 49 (1998), 61-67.
33. Magnani, H.N. Heparin-induced thrombocytopenia (HIT). An overview of 230 patients treated with Orgaran (Org 10172). Thromb. Haemost. 70 (1993). 554-561.
34. Magnani, H.N. Orgaran (Danaparoid sodium) use in tjie syndrome of heparin-induced-thromboctopenia. Proceedings of a workshop held in London 1996. Nov 1. Platelets 8 (1997), 74-81.
35. Magnani, H.N., R.J.R. Beijering. J.W. ten Gate. B.H. Chong Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. In Pifarré, R. (Ed.) New Anticoagulants for the cardiovascular patient (Hanley & Belfus Philadelphia 1997).
36. Magnani. H.N., B. Rieckhof Heparin-induzierte Thrombozytopenie Tatsächliche Ergebnisse im Vergleich zu theroretischen Überlegungen einer Therapie mit Orgaran®. J. Anästhesie Intensivbeh. 4 (1998), 23-28.
37. Markwardt, F. Hirudin The promising antithrombotic Cardiovasc. Drug. Rev. 10 (1992), 211-232.
38. Meuleman, D.G. Orgaran (Org 10172) Its pharmacological profile in experimental models. Haemostasis 22 (1992), 58-65.
39. Munver, R., I.e. Schulman, D.J. Wolf, T.K. Rosengart Heparin-induced thrombocytopenia and thrombosis presentation after cardiopulmonary bypass. Ann. Throe. Surg. 58 (1994), 1764-1766.
40. Nowak, G., E. Bucha Quantitative determination of hirudin in blood and body fluids. Semin. Thromb. Hemostas. 22 (1996). 197-202.
41. Olbrich. K., M. Wiersbitzky. W. Wacke, P. Eichler, H. Zinke, M. Schwock, B. Möx, G. Kraatz, W. Motz. A. Greinacher Atypical heparin-induced thrombocytopenia complicated by intracardiac thrombus, effectively treated with ultra low dose rt-PA lysis and recombinant hirudin (Lepirudin). Blood. Coagul. Fibrinolysis 9 (1998). 273-277.
42. Ortel, T.L B.H. Chong New treatment options for heparin-induced thrombocytopenia. Semin. Hematol. 35 (1998), 26-34.
43. 0-Yurvati, A.H., G.W. Laub, TJ. Southgate, LB. McGrath Heparinless cardiopulmonary bypass with ancrod. Ann. Thorac. Surg. 57 (1994). 1656-658.
44. Polgár, J., P. Eichler, A. Greinacher, K.J. Clemetson Adenosin diphosphate (ADP) and ADP receptor play a major role in platelet activation/aggregation induced by sera from heparin-induced thrombocytopenia patients. Blood 91 (1998), 549-554.
45. Pötzsch, B., F.C. Riess. H. Völpel, G. Müller-Berghaus, A. Greinacher Recombinant hirudin as anticoagulant during open heart surgery. Thromb. Haemost. 73 (1995). 1456 (abstract)
46. Pötzsch. B., K. Madiener. C. Seelig, CF. Riess, A. Greinacher, G. Müller-Berghaus Monitoring of r-hirudin during cardiopulmonary bypass-assessment of the whole blood ecarin clotting time. Thromb. Haemost. 77 (1997), 920-925.
47. Poullin, P., P.A. Pietri, P. Lefèvre Heparin-induced thrombocytopenia with thrombosis Successful treatment with plasma exchange [letter]. Brit. J. Haematol. 102 (1998), 630-631.
48. Ranze, O., P. Ranze, H.N. Magnani, A. Greinacher Heparin-induced thrombocytopenia in pediatric patients - a review of the literature and a new case treated with danaparoid sodium. Europ.J. Paediat. (1999).
49. Refludan Committee for proprietary medicinal products European public assessment report (EPAR). In The European Agency for the Evaluation of Medicinal Products. March 1997.
50. Riess, F.C., B. Pötzsch, K. Jäger, N. Bleese, W. Schaper, G. MüllerBerghaus Elimination von rekombinantem Hirudin aus der Blutzirkulation mittels Hämofiltration - Untersuchungen am Schweinemodell. Hämostaseologie 17 (1997), 200-204.
51. Rowlings. P.A., R. Mansberg, M.C. Rozenberg, S. Evans, B. Murray The use of a low molecular weight heparinoid (Org 10172) for extracorporeal procedures in patients with heparin dependent thrombocytopenia and thrombosis. Aust. N.Z. J. Med. 21 (1991), 52-54.
52. Schiffmann. H.. M. Unterhalt. K. Harms. H.R. Figulla, H. Völpel, A. Greinacher Erfolgreiche Behandlung einer Heparin-induzierten Thrombozytopenie Typ II im Kindesalter mit rekombinantem Hirudin. Monatsschr. Kinderheilkd. 145 (1997), 606-612.
53. Schmahl, K.S., A.K. Ganjoo, M.G. Harloff Orgaran (Org 10172) for cardiopulmonary bypass in heparin-induced thrombocytopenia Role of adjunctive plasmapheresis. J Cardiothorac Vase Anesth 11 (1997), 262-264. (letter).
54. Skoutakis, VA Danaparoid in the prevention of thromboembolic complications. Ann. Pharmacother. 31 (1997), 876-887.
55. Sodian. R., M. Lobe, K.F. Gorman, H. Riess, R. Hetzer Heparin induced thrombocytopenia. Experiences in 12 heart surgery patients. ASAIO J. 43 (1997). M 430-433.
56. Vanholder. R.C., A.A. Camez, N.M. Veys. J. Soria. M. Mirshahi, C.M. Soria. S. Ringoir Recombinant hirudin a specific thrombin inhibiting anticoagulant for hemodialysis. Kidney. Int. 45 (1994). 1754-1759.
57. Vanholder. R., A.A. Camez, N.M. Veys. A. van Loo. A.M. Dhondt, S. Ringoir Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. Thromb. Haemost. 77 (1997). 650-655.
58. van Wyk, V., P.N. Badenhorst, H.G. Luus. H.F. Kotzé A comparison between the use of recombinant hirudin and heparin during hemodialysis. Kidney Int. 48 (1995), 1338-1343.
59. von Bonsdorff, M., J. Stiekema, A. Harjanne, U. Alapiessa A new low molecular weight heparinoid Org 10172 as anticoagulant in hemodialysis. Int. J. Artif. Organs. 13 (1990), 103-108.
60. Warkentin, T.E., M.N. Levine. J. Hirsh, P. Horsewood. R.S. Roberts, M. Gent, J.G. Kelton Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. New Engl. J. Med. 332 (1995). 1330-1335.
61. Warkentin, T.E. Heparin-induced thrombocytopenia IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Transfus. Med. Rev. 10 (1996), 249-258.
62. Warkentin, T.E., J.G. Kelton A 14-year study of heparin-induced thrombocytopenia. Am. J. Med. 101 (1996), 502-507.
63. Warkentin; T.E. Heparin-induced thrombocytopenia. Pathogenesis, frequency, avoidance and management. Drug Safety 17 (1997), 325-341.
64. Warkentin. I.E. Clinical presentation of heparin-induced thrombocytopenia. Semin. Hematol. 35 (1998). Suppl 5, 9-16.
65. Warkentin, T.E., B.E. Chong, A. Greinacher Heparin-induced thrombocytopenia. Thromb. Haemost. 79 (1998), 1-7.
66. Wilde M.I., A. Markham Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs 54 (1997), 903-924.
67. Wissenschaftliche Information Orgaran® Thiemann Arzneimittel GmbH, Waltrop, Februar 1999.